S1 BIOPHARMA - Key Persons
Job Titles:
- Member of the MEDICAL ADVISORY BOARD
- Interim Chair, Department of Psychiatry & Neurobehavioral Sciences
Distinguished Fellow of the American Psychiatric Association
- Scientific Advisory Board As Chairman
Dr. Clayton joined S1 Biopharma's Scientific Advisory Board as Chairman in 2012. She is a past President of the International Society for the Study of Women's Sexual Health, the David C. Wilson Professor of Psychiatry in the Department of Psychiatry & Neurobehavioral Sciences at the University of Virginia and holds a secondary faculty appointment as professor of clinical obstetrics and gynecology. She has chaired or served on 25 academic committees. She has been featured in numerous publications, including The New York Times and The Wall Street Journal. Articles and abstracts authored by Dr. Clayton have appeared in numerous journals, including Academic Psychiatry, the American Journal of Psychiatry, Biological Psychiatry, the Journal of Clinical Psychiatry, the Journal of Sex and Marital Therapy, the Journal of Sexual Medicine and others. She has edited with Dr. Susan Kornstein Women's Mental Health: A Comprehensive Textbook. Dr. Clayton is on the editorial board for the Journal of Sex & Marital Therapy, the Journal of Sexual Medicine and Women's Health. She serves on the Board of Directors of the American Society of Clinical Psychopharmacology. She developed and validated the Changes in Sexual Functioning Questionnaire to measure sexual desire and function, which has been linguistically validated in more than 70 languages and utilized in over 90 clinical studies. Her book on women's sexuality for the general public, Satisfaction: Women, Sex, and the Quest for Intimacy was published by Ballantine Books/Random House in 2007. Her current research includes mood and anxiety disorders associated with reproductive-life events in women, sexual dysfunction related to illness and medications, and treatment of sexual disorders. Dr. Clayton obtained her M.D. at the University of Virginia School of Medicine and completed her residency training in Psychiatry at the University of Virginia.
Job Titles:
- Member of the International Society for the Study of Women 's Sexual Health / Member, International Academy of Sex Research / Member, Society for the Scientific Study of Sexuality
Dr. Meston is a past President of the International Society for the Study of Women's Sexual Health (ISSWSH), and an active member of the International Academy of Sex Research (IASR) and the Society for the Scientific Study of Sexuality (SSSS). Her book, Why Women Have Sex, which was published in 2009 with co-author David Buss, has been translated into nine foreign languages. She has published over 100 peer-reviewed scientific articles and given over 200 presentations both nationally and internationally on sexuality topics that span the areas of nervous system regulation of women's sexual arousal, drug effects on sexual response, the development of sexual self-views, body image influences on sexual functioning, monogamy, treatments for women with a history of childhood sexual abuse, and ethnic and religious influences on sexual behavior. Her research has appeared in the New York Times, Scientific American, Newsweek, and numerous women's and health magazines. Cindy M. Meston received her Ph.D. in Clinical Psychology from the University of British Columbia, a postdoctoral fellowship in Sexual and Reproductive Medicine at the University of Washington, School of Medicine, and a postdoctoral fellowship from the Social Science Research Council, Ford Foundation.
Job Titles:
- Member of the MEDICAL ADVISORY BOARD
- Professor of Psychiatry, Dept. of Psychiatry & Neurobehavioral Sciences, UVA
Professor, Clinical Obstetrics and Gynecology, UVA
Job Titles:
- Member of the BOARD of DIRECTORS
- CEO of Cerium Pharmaceuticals, Inc
Gregg A. Lapointe, CPA has served as a member of our board of directors since August 2014. Mr. Lapointe is currently CEO of Cerium Pharmaceuticals, Inc., a specialty pharmaceutical company, a position he has held since April 2012. Mr. Lapointe also currently serves on the Board of Directors of Soligenix, Inc., a publicly traded biopharmaceutical company, SciClone Pharmaceuticals, Inc., a publicly traded specialty pharmaceutical company, and Cambrooke Therapeutics, Inc., a privately held therapeutic nutrition company, and the Board of Trustees of the Keck Graduate Institute of Applied Life Sciences. He has previously served on the Board of Directors of the Pharmaceuticals Research and Manufacturers of America (PhRMA) and Questcor Pharmaceuticals, Inc., and has been a member of the Corporate Council of NORD (National Organization for Rare Disorders) for several years. He previously served in varying roles for Sigma-Tau Pharmaceuticals, Inc, a private biopharmaceutical company, from September 2001 through February 2012, including Chief Operating Officer from November 2003 to April 2008 and Chief Executive Officer from April 2008 to February 2012. From May, 1996 to August, 2001, he served as Vice President of Operations and Vice President, Controller of AstenJohnson, Inc. (formerly JWI Inc., a global manufacturer of paper machine clothing, advanced and filtration fabrics, filaments and drainage equipment). Prior to that, Mr. Lapointe spent several years in the Canadian medical products industry in both distribution and manufacturing. Mr. Lapointe began his career at Price Waterhouse. Mr. Lapointe received his B.A. degree in Commerce from Concordia University in Montreal, Canada, a graduate diploma in Accountancy from McGill University and his M.B.A. degree from Duke University. He is a C.P.A. in the state of Illinois and a Chartered Accountant in Ontario, Canada. Mr. Lapointe was selected to serve as a member of our Board of Directors because of his significant experience in the areas of global strategic planning and implementation, business development, corporate finance, and acquisitions, and his experience as an executive officer and board member in the pharmaceutical and medical products industries.
Job Titles:
- Member of the BOARD of DIRECTORS
- Managing Partner of Militia Hill Ventures LLC
- Member of Our Board of Directors
Jane H. Hollingsworth has served as a member of our board of directors since August 2014. Ms. Hollingsworth is currently Managing Partner of Militia Hill Ventures LLC, a privately held life sciences accelerator, a position she has held since October 2013, and Executive Chair of Immunome Inc., a privately held cancer immunotherapy company, a position she has held since October 2013. From October 2012 to December 2013, Ms. Hollingsworth was the President of JHH Technologies LLC, a privately held company offering advisory healthcare services. She served as CEO and was a co-founder of NuPathe Inc., a publicly traded biopharmaceutical company focused on diseases of the central nervous system, from January 2005 to September 2007. Prior to joining NuPathe Inc., Ms. Hollingsworth served as Executive Vice President and was a co-founder of Auxilium Pharmaceuticals Inc., a publicly traded biopharmaceutical company, and Vice President, Secretary and General Counsel of IBAH , Inc., a publicly traded clinical research organization that was sold to Omnicare Inc. in 1998. Ms. Hollingsworth began her career as a commercial litigator at the law firm of Montgomery, McCracken, Walker & Rhoads and as law clerk to the Honorable Jane R. Roth of the United States District Court for the District of Delaware. Ms. Hollingsworth received her B.A. degree in Spanish from Gettysburg College and her J.D. from Villanova University. Ms. Hollingsworth was selected to serve as a member of our Board of Directors because of her significant experience in the life sciences industry and as an executive officer of biotechnology and healthcare companies, including publicly-traded companies.
Job Titles:
- Chief Financial Officer
- Member of the MANAGEMENT Team
John F. Kaufmann, M.B.A. has served as our Chief Financial Officer since April 2012. From March 2010 to April 2012, he was the Finance Manager with Laureate Education, Inc., a multinational higher education holding company, where he served as a member of the senior management team responsible for the oversight of three operating subsidiaries. From February 2009 to March 2010, Mr. Kaufmann provided services to various charitable organizations, including acting as a Trustee. From August 2004 to September 2008, Mr. Kaufmann served as a finance executive for Fidelity Investments Corp. where he was responsible for a $200 million budget. Mr. Kaufmann received his M.B.A. in Finance from Boston University and his B.A. in History from Dartmouth College.
Job Titles:
- Director, Maryland Center for Sexual Health
Associate Professor of Psychiatry, Johns Hopkins University School of Medicine
Dr. DeRogatis joined the S1 Scientific Advisory Board in 2012. He was in the vanguard of early attending clinicians at the Johns Hopkins Sexual Behaviors Consultation Unit, which he directed for several years, and served on the faculty at Johns Hopkins for 21 years. He was also the founder and Director of the Division of Medical Psychology, and Chief Psychologist of the Johns Hopkins Hospital. Most recently, Dr. DeRogatis accepted the Directorship of the Maryland Center for Sexual Health in suburban Baltimore. Over the past several decades, Dr. DeRogatis has authored and published more than a dozen psychological measuring instruments, including the Hopkins Symptom Checklist and the DeRogatis Interview for Sexual Functioning. He has authored more than 150 scientific papers, many of them focused on diagnostic and treatment issues in sexual medicine. He has been the recipient of federal grant awards, including grants from the NIMH and NCI, and has served as principal investigator on numerous industry- sponsored multi-center drug trials focused on sexual dysfunction. Leonard R. DeRogatis received his Ph.D. from Catholic University.
Job Titles:
- Member of the Ohio State Medical Association
Dr. Katz is a board-certified obstetrician-gynecologist practicing in Cincinnati. She has been a lead investigator and author of numerous large, late-phase trials of treatments for HSDD in women. Dr. Katz is a member and past president of the Ohio State Medical Association, an Ohio Delegate to the American Medical Association and a Fellow of the American College of Obstetrics/Gynecology. She is also active in community affairs and serves as a Board member of the Greater Cincinnati Foundation and as Vice-Chair of the Board of Healthpath Foundation, a supporting organization of The Greater Cincinnati Foundation that works to advance the health of underserved Ohioans. Dr. Katz obtained her M.D. from the University of Toledo (OH) College Of Medicine and completed her residency in Obstetrics/Gynecology at Emory University in Atlanta.
Job Titles:
- Chief Executive Officer
- Member of the BOARD of DIRECTORS
- Member of the MANAGEMENT Team
- CEO of S1 Biopharma, to Present at BIO - Europe 2015 Conference
Nicolas G. Sitchon, M.A., M.B.A. has served as Chairman of our board of directors and as our President and Chief Executive Officer since our founding in October 2010. From October 2008 to October 2010, Mr. Sitchon performed services in anticipation of incorporation of our company and related to the development of our lead product candidate, Lorexys TM. From April 2006 to October 2008, Mr. Sitchon was Global Research & Development Controller at Bayer HealthCare Consumer Care, a division of Bayer AG. Prior to that time, Mr. Sitchon held positions in marketing, information technology, business intelligence and business planning in the cardiovascular and neuroscience franchises of the Pharmaceuticals division of Novartis Corporation. Mr. Sitchon received his M.A. in Medical Science from the Boston University School of Medicine and his M.B.A. from the Boston University School of Management. He completed his undergraduate studies at the University of California, Berkeley. Mr. Sitchon was selected to serve as a member of our Board of Directors because of his role in developing, and his extensive knowledge regarding, our product candidates; his experience as our executive officer; because of his proven ability to pursue the development of product candidates in an efficient manner using minimal capital; and because of his advanced degrees in science and business.
Job Titles:
- Chief Medical Officer
- Member of the MANAGEMENT Team
Robert E. Pyke, M.D., Ph.D. has served as our Chief Medical Officer since April 2012 and as a member of our advisory board since October 2011. Dr. Pyke has more than 30 years of experience in the pharmaceutical and biotechnology industries. He has contributed to FDA approvals of multiple drugs developed by Parke-Davis, Bristol-Myers Squibb and The Upjohn Company. From April 1996 to June 2011, Dr. Pyke was Director of Clinical Research at Boehringer Ingelheim Pharmaceuticals, where he led the flibanserin worldwide premenopausal HSDD clinical program for five years and produced more than 60 publications. Before Boehringer Ingelheim, Dr. Pyke worked with several large pharmaceutical companies, where he developed novel analgesics, anxiolytics, antidepressants, antipsychotics and treatments for benzodiazepine and cocaine dependence. He headed the CNS R&D Drug Safety unit at Bristol-Myers Squibb and the medical affairs safety unit at Upjohn. Dr. Pyke's independent CRO performed research for Searle in connection with the FDA approval of Misoprostil to prevent peptic ulcers. Throughout his business career, Dr. Pyke has continued his clinical practice with the treatment of anxiety, depression and substance abuse. He is a member of the International Society for Sexual Medicine and the International Society for the Study of Women's Sexual Health. Dr. Pyke received his Ph.D. from the University of Wisconsin, Madison, earned his M.D. at the University of Miami and completed his medical training in Internal Medicine at the University of Michigan.
Job Titles:
- Professor of Psychiatry, Case Western Reserve School of Medicine / Member, DSM - V Taskforce / Editor, Journal of Sex and Marital Therapy
Robert Taylor Segraves, MD, PhD received his medical training at Vanderbilt University in Nashville, Tennessee and completed his psychiatric residency at the University of Chicago. He also obtained a PhD in Psycholgy at the University of London. He has spent most of his career studying and treating sexual disorders. He was on the American Psychiatric Association Taskforce on Psychosexual Disorders for DSM III R DSM IV , DSM IV TR and DSM V.. He is a past president of the Society for Sex Therapy and Research, and is the current editor of the Journal of Sex and Marital Therapy.
He has over 200 publications in the area of human sexuality , numerous national and international presentations, and five texts (the latest of which is Clinical Manual of Sexual Disorders, co-edited with Richard Balon ). He is Professor Emeritus of Psychiatry at Case Western Reserve University in Cleveland , Ohio.